Literature DB >> 31520176

Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.

Tetsuya Yumioka1, Masashi Honda2, Ryoma Nishikawa1, Shogo Teraoka1, Yusuke Kimura1, Hideto Iwamoto1, Shuichi Morizane1, Katsuya Hikita1, Atsushi Takenaka1.   

Abstract

BACKGROUND: To evaluate the relationship between sarcopenia and myelosuppression or between sarcopenia and survival outcomes in patients with urothelial carcinoma (UC) undergoing chemotherapy with gemcitabine plus cisplatin (GC) or carboplatin (GCa).
METHODS: We evaluated 80 patients with UC who underwent chemotherapy between 2013 and 2017 at our institution. In total, 53 patients had metastatic UC and were ultimately included in the study. Predictive factors for myelosuppression (neutropenia, thrombocytopenia, and anemia) in all patients and overall survival (OS) in metastatic UC patients were analyzed. Sarcopenia was assessed on computed tomography before chemotherapy. Each patient's total psoas area was measured at the lumbar vertebrae (L3) and sarcopenia was defined as median values or lower. Predictive factors for myelosuppression were assessed using logistic regression analysis and survival was evaluated using Cox regression analysis.
RESULTS: The patients' mean age was 71.6 years (range 44.4-89.2 years). Of the initial 80 patients, 39 were diagnosed with sarcopenia and 26 of 53 patients with metastatic UC were diagnosed with sarcopenia. Sarcopenia was an independent predictive factor (P = 0.030; odds ratio, 3.526; 95% confidence interval [CI] 1.128-11.01) for neutropenia on multivariate analysis. Patients without sarcopenia had a significantly longer OS compared to those with sarcopenia (P = 0.013). Sarcopenia and albumin (P = 0.045, 0.023; hazard ratio (HR), 2.309, 2.652; 95% CI 1.021-5.225, 1.141-6.165, respectively) were independent predictors of OS in multivariate analysis.
CONCLUSIONS: Sarcopenia was predictive for neutropenia associated with GC or GCa in UC patients and OS in metastatic UC.

Entities:  

Keywords:  Chemotherapy; Hematologic side effect; Overall survival; Sarcopenia; Urothelial carcinoma

Mesh:

Substances:

Year:  2019        PMID: 31520176     DOI: 10.1007/s10147-019-01544-5

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  31 in total

1.  Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

Authors:  Ron H J Mathijssen; Floris A de Jong; Walter J Loos; Jessica M van der Bol; Jaap Verweij; Alex Sparreboom
Journal:  Oncologist       Date:  2007-08

2.  Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.

Authors:  Megumi Hori; Tomohiro Matsuda; Akiko Shibata; Kota Katanoda; Tomotaka Sobue; Hiroshi Nishimoto
Journal:  Jpn J Clin Oncol       Date:  2015-07-03       Impact factor: 3.019

3.  Preoperative sarcopenia status is associated with lymphovascular invasion in upper tract urothelial carcinoma patients treated with radical nephroureterectomy.

Authors:  Tadatsugu Anno; Eiji Kikuchi; Keishiro Fukumoto; Koichiro Ogihara; Mototsugu Oya
Journal:  Can Urol Assoc J       Date:  2017-12-22       Impact factor: 1.862

4.  Sarcopenia as a prognostic factor among patients with stage III melanoma.

Authors:  Michael S Sabel; Jay Lee; Shijie Cai; Michael J Englesbe; Stephen Holcombe; Stewart Wang
Journal:  Ann Surg Oncol       Date:  2011-08-06       Impact factor: 5.344

5.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

Authors:  Hans von der Maase; Lisa Sengelov; James T Roberts; Sergio Ricci; Luigi Dogliotti; T Oliver; Malcolm J Moore; Annamaria Zimmermann; Michael Arning
Journal:  J Clin Oncol       Date:  2005-07-20       Impact factor: 44.544

6.  Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.

Authors:  B H L Tan; K Brammer; N Randhawa; N T Welch; S L Parsons; E J James; J A Catton
Journal:  Eur J Surg Oncol       Date:  2014-11-26       Impact factor: 4.424

7.  The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer.

Authors:  Egidio Del Fabbro; Henrique Parsons; Carla L Warneke; Kalyan Pulivarthi; Jennifer K Litton; Rony Dev; Shana L Palla; Abenaa Brewster; Eduardo Bruera
Journal:  Oncologist       Date:  2012-08-17

8.  Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study.

Authors:  Hiroki Ishihara; Tsunenori Kondo; Kenji Omae; Toshio Takagi; Junpei Iizuka; Hirohito Kobayashi; Yasunobu Hashimoto; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2016-07-15       Impact factor: 3.402

9.  Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.

Authors:  Olivier Mir; Romain Coriat; Benoit Blanchet; Jean-Philippe Durand; Pascaline Boudou-Rouquette; Judith Michels; Stanislas Ropert; Michel Vidal; Stanislas Pol; Stanislas Chaussade; François Goldwasser
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

Review 10.  Sarcopenia: definition, epidemiology, and pathophysiology.

Authors:  Tae Nyun Kim; Kyung Mook Choi
Journal:  J Bone Metab       Date:  2013-05-13
View more
  1 in total

1.  Sarcopenia is associated with survival in patients with urothelial carcinoma treated with systemic chemotherapy.

Authors:  Ryutaro Shimizu; Masashi Honda; Shogo Teraoka; Tetsuya Yumioka; Noriya Yamaguchi; Bunya Kawamoto; Hideto Iwamoto; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2021-10-04       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.